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Abstract
White adipose tissue (WAT) plays a fundamental role in maintaining energy balance and
important endocrine functions. The loss of WAT modifies adipokine secretion and disrupts
homeostasis, potentially leading to severe metabolic effects and a reduced quality of life.
Doxorubicin is a chemotherapeutic agent used clinically because of its good effectiveness
against various types of cancer. However, doxorubicin has deleterious effects in many
healthy tissues, including WAT, liver, and skeletal and cardiac muscles. Our objective was
to investigate the effects of doxorubicin on white adipocytes through in vivo and in vitro
experiments. Doxorubicin reduced the uptake of glucose by retroperitoneal adipocytes and
3T3-L1 cells via the inhibition of AMP-activated protein kinase Thr172 phosphorylation and
glucose transporter 4 content. Doxorubicin also reduced the serum level of adiponectin
and, to a greater extent, the expression of genes encoding lipogenic (Fas and Acc) and adi-
pogenic factors (Pparg, C/ebpa, and Srebp1c) in retroperitoneal adipose tissue. In addition,
doxorubicin inhibited both lipogenesis and lipolysis and reduced the hormone-sensitive
lipase and adipose tissue triacylglycerol lipase protein levels. Therefore, our results demon-
strate the impact of doxorubicin on WAT. These results are important to understand some
side effects observed in patients receiving chemotherapy and should encourage new adju-
vant treatments that aim to inhibit these side effects.
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Introduction
White adipose tissue (WAT) is a complex organ, that is composed by mature white adipocytes,
approximately between one to two thirds of total WAT cells [1]. The other type of cells that
make up the adipose tissue are fibroblasts, macrophages, pre adipocytes and endothelial cells
[2]. This tissue has a high capacity for remodeling in response to different stress, such as hyp-
oxia, loss or gain of mass, and excess or deprivation of nutrients [3].
The WAT is the major energy reservoir in animals [2]. Moreover, this tissue regulates sev-
eral metabolic processes that are necessary for maintaining energetic homeostasis. WAT is
responsible for approximately 15% of all glucose metabolism, and this metabolic substrate is
utilized for both energy production and storage in adipocytes [4–5]. In addition, the storage,
mobilization and supply of fatty acids are regulated by WAT. The process of storage is termed
lipogenesis, which is a complex metabolic route to fatty acid synthesis (mainly from glucose)
and storage; and on the other hand lipolysis is a route for the mobilization and supply of free
fatty acids by other organs [1, 4, 6].
Finally, the WAT mass is also influenced by adipogenesis, which is a process that leads to
differentiation of the preadipocytes in mature adipocytes. This process is managed by several
hormones (insulin; corticosterone and other growth factors) and a complex activation in a
time-dependent manner of diverse transcription factors (C/EBPa,b,g; SREBP-1c and PPARg
encodes CCAAT enhancer binding protein alpha, beta, gamma; Sterol-regulatory-element-
binding protein 1c and Peroxisome-proliferator-activated receptor gamma) [7–8].
The WAT cross talks with different organs in the body, and since 1994 its role as an endo-
crine organ was established; since it produces and releases different adipokines [9]. The exces-
sive gain or loss of WAT modifies the secretion of adipokines and cytokines, and can thus alter
appetite, reproduction, circadian rhythms, energy expenditures, and inflammation, resulting in
a reduced quality of life [9–10]
The chemotherapeutic agent doxorubicin was developed in the 1960s, and it is currently used
widely in clinical practice because of its strong antitumor activity. This agent exhibits poor tumor
selectivity and is therefore used to treat a variety of malignancies, including breast cancer, lym-
phoblastic leukemia, breast carcinoma, ovarian carcinoma, and both Hodgkin and non-Hodgkin
lymphomas [11–12]. Patients undergoing doxorubicin chemotherapy commonly develop symp-
toms such as vomiting, diarrhea, irregular heartbeat, mouth sores, abnormal bleeding, and swell-
ing of the feet or ankles [13–14]. Furthermore, doxorubicin treatment is characterized by
deleterious side effects in healthy tissues, including sarcopenia, diabetes, nephrotoxicity [15–16],
hepatotoxicity [17], and severe cardiocytotoxicity, according to reports as early as 1974 [18].
The other chemoterapic drug, which also possesses a large spectrum, is cisplatin, leads to an
impairment of lipid metabolism, with an increase in lipolysis, and an inhibition of lipogenesis
and adipogenesis due to loss of WAT and body weight [19] in mice without tumors. This phe-
nomenon is very similar with a cachexia syndrome (cachexia-like syndrome),which is a com-
plex metabolic disorder in which patients exhibit weight loss and depletion of adipose tissue
and skeletal muscle [19]; in addition, severe symptoms such as anorexia and extreme fatigue
may occur in patients with cancer. These effects lead to poor survival rates and elevated toxicity
associated with treatment [14].
In accordance with metabolic disorders caused by doxorubicin treatment, data collected in
our laboratory have demonstrated that doxorubicin can induce hyperglycemia, decrease insulin
sensitivity, and increase levels of nonesterified fatty acids. Circulating glucose uptake occurs in
the skeletal muscle and adipose tissue in response to insulin stimuli. Recently, we demonstrated
that AMP-activated protein kinase (AMPK) and glucose transporter 4 (GLUT-4) signaling in
skeletal muscle is disrupted by doxorubicin treatment [20].
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Based on this characterization of metabolic disturbances after doxorubicin treatment, the
aim of this study was to investigate the effects of doxorubicin onWAT at the cellular level
through in vivo and in vitro investigations of processes such as lipolysis, lipogenesis, glucose
uptake, and adipogenesis.
Results
Doxorubicin promotes toxicity in 3T3L1 cells
We initially observed that doxorubicin caused considerable lethality in 3T3-L1 cells after 96-h
incubation and was nontoxic only at doses<1μM (Fig 1A); similarly, intraperitoneal (i.p.)
doxorubicin administration [15 mg/kg body weight (b.w.)] promoted a reduction in adipocyte
size in Wistar rats (Fig 1B).
Doxorubicin reduced glucose uptake
Retroperitoneal adipose tissues from rats treated with doxorubicin (72 h) exhibited reduced
glucose uptake after insulin stimulation (Fig 2A). Even at low doses (1uM) and over short
Fig 1. Doxorubicin promotes toxicity in 3T3L1 cell. Cell viability after 96 hours (A) of doxorubicin (DX)
incubation. Concentrations range from 0.001 to 100 uM. Cell viability was assessed by MTT assay and
normalized adopting the control absorbance as 100% survival. Values represent the mean ± standard
deviation of 3 independent experiments. Adipocyte size of cells from the retroperitoneal adipose tissues (B) of
rats treated with a single dose of doxorubicin (15 mg/kg body weight ip), euthanized 72 hours after
administration. Values represent the mean ± standard deviation of 5 to 6 experiments. The groups were
compared using the one-Way ANOVA followed by Dunnett's (A) and t test (B).*p <0,05, **p <0.01,
*** p <0.001.
doi:10.1371/journal.pone.0151548.g001
Fig 2. Reduction of glucose uptake by doxorubicin in adipocytes.Glucose uptake from the
retroperitoneal adipose tissues of rats (A) and glucose uptake from 3T3L1 cells (B and C). Protein expression
of AMPK thr 172 phosphorylated, total content of GLUT4 and FABP4 from retroperitoneal adipose tissues of
rats (D) and protein expression of AMPK threonine 172 phosphorylated, total content of GLUT4 and GAPDH
from 3T3L1 cells (E). Adipocytes from the retroperitoneal adipose tissues of rats treated with a single dose of
doxorubicin (15 mg/kg body weight ip), euthanized 72 hours after administration. The glucose uptake was
measured by uptake of 2-DG with and without insulin stimulation (100nMol) in isolated adipocytes and 3T3L1
cells. 3T3L1 cells were incubated with doxorubicin (1uM) for 30 minutes (B) and 24 hours (C and E), after
differentiation into mature adipocytes. Values represent the mean ± standard deviation of 5 to 6 experiments
(A, B and C). Figures represents 4 experiments per group (D and E). The groups were compared using two-
way ANOVA followed by Dunn’s (A, B, and C). *p<0.05 and **p<0.01.
doi:10.1371/journal.pone.0151548.g002
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periods (30 min or 24 h), doxorubicin treatment reduced glucose uptake after insulin stimula-
tion (Fig 2B and 2C).
Doxorubicin treatment decreases AMPK phosphorylation and GLUT-4
expression in vivo
GLUT-4 expression and AMPK Thr172 phosphorylation were reduced in the retroperitoneal
adipose tissues of rats treated with doxorubicin (Fig 2D) but not in treated 3T3-L1 cells (Fig
2E). In keeping with the inhibition of AMPK Thr172 phosphorylation, we observed that doxo-
rubicin reduced adiponectin levels in both the sera (Fig 3A) and retroperitoneal adipose tissues
(Fig 3B) of rats. Low-dose (1uM) doxorubicin treatment over a 24-h period also suppressed
levels of adiponectin secreted into the culture medium (Fig 3C).
Doxorubicin affects lipogenesis
In addition, doxorubicin treatment compromised several metabolic pathways. Rats injected
with doxorubicin exhibited reduced lipid synthesis from palmitate (ex vivo; Fig 4). Likewise,
3T3-L1 cells treated with doxorubicin exhibited lower de novo expression levels of genes associ-
ated with lipogenesis regulation. For instance, both Fas (encodes fatty acid synthase; Fig 5A)
and Acc (encodes acetyl-CoA carboxylase; Fig 5B) expression were inhibited in 3T3-L1 cells
from 96 h to 12 days after the induction of differentiation and doxorubicin treatment (Fig 6).
Adipogenesisis compromised by doxorubicin
Adipogenesis was also inhibited by doxorubicin. Oil red staining showed significant disruption
of 3T3-L1 differentiation after a 12-day incubation with doxorubicin (1uM; Fig 7). In addition,
doxorubicin decreased the expression of genes associated with adipogenesis modulation; in
Fig 3. Doxorubicin decreased the adiponectin levels. Adiponectin protein levels in serum (A) and
retroperitoneal adipose tissue (B) of rats 72 hours after treatment with doxorubicin (15mg/kg). Concentration
of adiponectin released into culture medium (C) with doxorubicin (DX) 1uM for 24 hours, after differentiation
into mature adipocytes. Data are mean ± standard deviation of 6 experiments. The groups were compared
using the Student t test.** p <0.01, *** p <0.001.
doi:10.1371/journal.pone.0151548.g003
Fig 4. Doxorubicin reduces lipogenesis. Fatty acid incorporation into triacylglycerol (TAG) in isolated
adipocytes of retroperitoneal adipose tissue from rats after 72 hours of doxorubicin (DX) (15 mg/kg weight) or
saline (Control) injection i.p. Data are mean ± standard deviation of 4 to 6 experiments. The groups were
compared using the Student t test, *p<0.05.
doi:10.1371/journal.pone.0151548.g004
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particular, the expression levels of Pparg (Fig 7A) and C/ebpa (Fig 7B) were strongly reduced
following doxorubicin treatment at all three time points, whereas Srebp1c expression was only
inhibited after a 24 h incubation with doxorubicin (Fig 7C).
Doxorubicin modifies the lipolysis process
Finally, we determined that lipolysis was also inhibited by doxorubicin. Although we expected
an increase in activity in this pathway, we observed that doxorubicin reduced both basal and
isoproterenol-stimulated lipolysis in isolated retroperitoneal cells (Fig 8A). Whereas two differ-
ent doses of doxorubicin (0.1 and 1uM) failed to induce death in 3T3L1 cells (Fig 8C), both
doses reduced lipolysis in both the presence and absence of isoproterenol stimulation (Fig 8B).
Similarly, the protein levels of hormone-sensitive lipase (HSL) p565 and p660, which are phos-
phorylated in retroperitoneal adipose tissue, were reduced by doxorubicin treatment, as was
the protein level of adipose tissue triacylglycerol lipase (ATGL; Fig 8D).
Methods
Animals
The Experimental Research Committee of the University of São Paulo approved all procedures
for the care of the animals used in this study. All experiments were performed in accordance
with the approved guidelines of animal ethic committee the ICB-USP, registered under n°5, fls
15, book 03 of this Institute.
26 male Wistar rats approximately 14 weeks of age (weighing 350–380 g), obtained from
Biomedical Sciences Institute of University of São Paulo, were housed four per cage in an ani-
mal room under 12:12-h light-dark cycle (lights on at 06:00). Rats were randomly divided into
Fig 5. Doxorubicin reduces lipogenic enzymes.Gene expression of lipogenic enzymes Fas (A) and Acc
(B) at 24 hours, 96 hours and 12 days after induction of cell differentiation in 3T3L1 cells treated with 1uM of
doxorubicin. The gene expression was evaluated by real time PCR. Data are mean ± standard deviation of 4
to 6 experiments. The groups were compared using the Two way ANOVA followed by Bonferroni post test,
*p <0.05, **p<0.01 and ***p<0.001.
doi:10.1371/journal.pone.0151548.g005
Fig 6. Doxorubicin impairs lipogenesis. 3T3L1 cells stained with oil red. 3T3L1 cell were treated with
doxorubicin (DX) 1uM or PBS (control) for 12 days after the differentiation cocktail. Photos were obtained by
optical microscopy at a resolution of 200X.
doi:10.1371/journal.pone.0151548.g006
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two groups: saline control (CT) (n = 13); and the doxorubicin group (DX) (n = 13). After the
acclimation period, the DX received 15mg/kg, i.p., doxorubicin chloridrate (Eurofarma Labo-
ratory, Campinas, Brazil); the CT animals received an equal volume of saline.
Rats received food (chow pellet diet; Nuvilab CR1, Nuvital SA, Colombo, PR, Brazil) and
water ad libitum. Food intake and body weight were assessed daily. Furthermore, after injection
with doxorubicin, the health and well-being of the rats were monitored daily.
Rats were euthanized by decapitation 72 hours after the doxorubicin treatment, after which
the retroperitoneal adipose tissue was removed, weighed, flash frozen in liquid nitrogen and
stored at -80°C. Whole blood was drawn and centrifuged, and serum was removed and kept
frozen at –80°C for later analysis.
Adipocyte isolation
For adipocyte isolation, retroperitoneal fat pads from rats were dissolved in Dulbeccos modi-
fied Eagle Medium (DMEM) (Sigma, St. Louis, USA) supplemented with HEPES (20 mM),
sodium pyruvate (2 mM), bovine serum albumin (BSA, 1%), and collagenase type II (1 mg/
mL), in an orbital bath shaker with a pH of 7.4 and at 37°C. Isolated adipocytes were filtered
and washed three times in the same buffer without collagenase. The adipocytes were photo-
graphed under an optical microscope (×100 magnification) using a microscope camera
Fig 7. Adipogenesis is compromised by doxorubicin in 3T3L1 cells.Gene expression of adipogenics
factors Ppparg (A), C/ebpa (B) and Srebp1c (C) at 24 hours, 96 hours and 12 days after induction of cell
differentiation in 3T3L1 cells treated with 1uM of doxorubicin. The gene expression was evaluated by real
time PCR. Data are mean ± standard deviation of 4 to 6 experiments. The groups were compared using the
Two way ANOVA followed by Bonferroni post test, *p<0.05, **p<0.01 and ***p<0.001.
doi:10.1371/journal.pone.0151548.g007
Fig 8. Doxorubicin inhibits the lipolysis process.Glycerol released in assay of lipolysis the adipocytes
isolated from retroperitoneal adipose tissue of rats after 72 hours of doxorubicin administration (15mg/kg of
weighti.p), with or without isoproterenol stimulation (10uM) for 30 minutes (A). Concentration of glycerol
(B) and lactate dehydrogenase LDH in incubation medium of 3T3L1 (C). Lipolysis was stimulated with
isoproterenol (Iso) 10uM with doxorubicin (DX) at concentrations of 0.1 and 1uM for 24 hours, the
parameters are normalized by the concentration of protein extracted from the cells. Values represent the
mean ± standard deviation of 4 to 8 experiments. The groups were compared using the One-Way ANOVA
followed by Bonferroni post test. *p<0.05, **p<0.01, ***p<0.001 (A, B and C). Protein expression of HSL
phosphorylated at residue Ser-565, Ser-660, total HSL, ATGL and GAPDH (D). Proteins extracted from
retroperitoneal adipose tissue of rats 72 hours after treatment with doxorubicin (15mg/kg). Figure represents
4 experiments per group (D).
doi:10.1371/journal.pone.0151548.g008
Impact of Doxorubicin in Adipose Tissue
PLOS ONE | DOI:10.1371/journal.pone.0151548 March 25, 2016 6 / 14
(Moticam 1000; Motic, Richmond, British Columbia, Canada), and the adipocyte diameter
average was determined by measuring 50 cells using Motic-Images Plus 2.0 software.
Cell culture
3T3-L1 cells were from ATCC (Manassas, USA)cells between 5–10 passages were plated
(2x104) in 24-well, 12-well or 6-well plates, maintained in Dulbecco’s modified Eagle medium
(Sigma, St. Louis, USA) at 37°C, 5% CO2 and supplemented with 10% fetal bovine serum (FBS)
and 3% antibiotic solution (penicillin/streptomycin). The cells were allowed to reach conflu-
ence and after two days, a differentiation medium containing 10% FBS, 3% antibiotic, IBMX
(0.5mM), insulin (1.6uM) and dexamethasone (1uM) was added to the plates for 2–4 days.
Then, the cells were maintained in a modified DMEM feeding containing 10% FBS, 3% antibi-
otic and insulin (0.4uM) until the 11th day, with medium exchanges every 2nd day. On the
11thday cells were maintained in a DMEM feeding with 0.5% FBS for 24 hours and the experi-
mental procedures performed.
MTT Assay
For the assessment of cell viability, differentiated 3T3-L1 cells were incubated with different
concentrations of doxorubicin (0.001 to 100uMol) for 72 and 96 hours in differentiation
medium. After these periods, the cell medium was replaced by PBS containing 0.05 mg/mL of
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)(Solon, OH, USA) and
cultivated for another 3 hours in the cells’ incubator. Supernatant was removed and isopropa-
nol/HCl (11 M) was added, the absorbance was measured at 595 nm. The effect of the doxoru-
bicin on cell viability was relativized by control group.
2-Deoxy-D-glucose (2-DG) uptake
Differentiated 3T3-L1 cells (~8×105 cells/well) or primary retroperitoneal adipocytes (106 cells/
mL) were washed in PBS and incubated with or without insulin (100 nmol/L) in a buffer com-
posed of (mM): 140 NaCl, 20 Hepes, 5 KCl, 2.5 MgSO4, 1 CaCl2, BSA 1% (pH 7.4), for 20 min
at 37°C. Subsequently, 2-deoxy-D-[3H]-glucose (0.4 mmol/L, 1850 Bq/tube or well) (Amer-
shan Bioscience, UK) was added and the reaction was allowed to occur for exactly 4 and 3 min,
for 3T3-L1 and primary adipocytes, respectively. The reaction was interrupted by adding 250-
μl ice-cold phloretin (0.3mmol/L in Earle's salts, HEPES 10mm, BSA 1% and DMSO 0.05%).
The 3T3-L1 cells were washed with cold PBS, 300uLNaOH 50mM was added to each well, the
plate was rotated for 20 min and 250uL was collected to measure the radioactivity (1450 LSC,
CouterMicroBeta, Trilux, PerkinElmer). For retroperitoneal primary adipocytes, 200-ul doses
of this final mixture were layered with 200ul of silicone oil (density of 0.963 mg/ml) in micro-
fuge tubes and centrifuged for 10 sec at 11,000g. The cell pellet on top of the oil layer was col-
lected, transferred to vials containing the scintillation cocktail for radioactivity measurement
by a beta counter. The results are expressed as umol of glucose per 1x106 cells and pmol per
cm2, for 3T3-L1 and retroperitoneal primary adipocytes, respectively.
Protein analysis by Western Blotting
Retroperitoneal adipose tissues and 3T3-L1 was removed, then homogenized in extraction
buffer containing protease and phosphatase inhibitors. Extracts were centrifuged and protein
determination in the supernatants was performed by the Bradford assay (Bio-Rad Laboratories,
Hercules, CA, USA). The proteins were treated with a Laemmli sample buffer containing
dithiothreitol and boiled for 5 min before being loaded into a 10% SDS-PAGE in a Bio-Rad
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miniature slab gel apparatus. The electrotransfer of proteins from the gel to nitrocellulose was
performed. The nitrocellulose membranes were incubate overnight at 4°C with antibodies
against GLUT-4, ATGL, phospho AMPK-T172, phospho HSL-S565, HSL-S660, total HSL and
FABP4 obtained from Cell Signaling Technology1 (Danvers, MA, USA), and GAPDH
obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Afterwards, the blots were
incubated with a peroxidase-conjugated secondary antibody for (1:5000) 1h. Specific bands
were detected by chemoluminescence and visualization/capture was performed by exposure of
the membranes to RX films. Band intensities were quantified by optical densitometry of devel-
oped autoradiographs (Scion Image software-Scion Corporation, Frederick, Md., USA).
Adipose tissue and serum adiponectin
Frozen tissues (0.1g) were homogenized in the RIPA buffer (0.625% Nonidet P-40, 0.625%
sodium deoxycholate,6.25mM sodium phosphate, and 1 mMethylenediaminetetraacetic acid at
pH 7.4) containing 10ug/ml of protease inhibitor cocktail (Sigma-Aldrich, St. Louis, Missouri).
Homogenates were centrifuged, the supernatant was saved, and protein concentration was
determined using the Bradford assay (Bio-Rad, Hercules, California) with bovine serum albu-
min as reference. The quantitative assessment of adiponectin in retroperitoneal adipose tissue
and serum were carried out by ELISA (DuoSet ELISA, R&D Systems, Minneapolis, MN). All
samples were run as duplicates, and mean value was reported.
Quantitative Real-Time PCR
Total RNA from 3T3L1 cells was extracted with the reagent Trizol (Invitrogen Life Technolo-
gies, Carlsbad, USA), and reverse transcribed to cDNA using a High-Capacity cDNA kit
(Applied Biosystems, Warrington, UK). The RNA analysis by agarose gel electrophoresis are
shown in S2 Fig. Lipogenic enzymes—Fas and Acc—and adipogenic factors–Pparg, C/ebpa and
Srebp1c. Gene expression was evaluated by real-time PCR using a Rotor Gene (Qiagen) and
SYBR Green as the fluorescent dye. Quantification of gene expression was carried with RPL-19
gene as a control and is shown in S2 Fig. Primer sequences are shown in Table 1.
Lipogenesis
Primary retroperitoneal adipocytes (106 cells/mL) were incubated in Krebs/Ringer/phosphate
buffer (BSA 1%, 2mM glucose, 200uM [1-14C]-Palmitate, 1850 Bq/tube at pH 7.4) for 2 h at
37°C in a water bath. At the end of incubation, the mixture was transferred to 1.5mL tubes con-
taining 400uL of silicone oil and centrifuged for 30s. The cell pellet on the top of the oil layer
was transferred to polypropylene tubes containing 2.5mL of Dole's reagent [isopropanol:n-
heptane:H2SO4 (4:1:0.25, vol/vol/vol)] for lipid extraction. After addition of n-heptane
(1.5mL) and distilled water (1.5mL), the tubes were vortexed and the mixture decanted for
Table 1. Primer sequences.
GENE 5’-FORWARD PRIMER-3’ 5’-REVERSE PRIMER-3’
Rpl-19 CAATGCCAACTCCCGTCA GTGTTTTTCCGGCAACGAG
Fas GATTCGGTGTATCCTGCTGTC CATGCTTTAGCACCTGCTGT
Acca CCAGCAGATTGCCAACATC ACTTCGGTACCTCTGCACCA
Pparg ATCTTAACTGCCGGATCCAC CAAACCTGATGGCATTGTGAG
C/ebpa TAGGTTTCTGGGCTTTGTGG GATGGATCGATTGTGCTTCA
Srebp1c TGGACCACAGAAAGGTGGA ATGGCCTTGTCAATGGAACT
doi:10.1371/journal.pone.0151548.t001
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5min. An aliquot of the upper phase was collected into a scintillation vial for the determination
of radioactivity trapped into TAG (1450 LSC, CouterMicroBeta, Trilux; PerkinElmer). Results
are expressed as nmol of palmitate incorporated into TAG per 1x106 cells/h.
Oil Red O staining and lipid content quantification
Oil Red O staining (Sigma-Aldrich) assessed cellular lipid content. After 12 days of differentia-
tion, the cells were washed, fixed in 4% paraformaldehyde for 1 h and stained with an Oil Red
O working solution for 1 h. After washing 3 times with PBS, the cells were photographed with
a light microscope (Olympus, Osaka, Japan). The size and number of lipid droplets were ana-
lyzed using Image Pro Plus 5.02.
Lipolysis
Lipolysis was estimated as the rate of glycerol release in the incubation medium. For this, retro-
peritoneal adipocytes (1 x 106 cells/ml) were incubated in Krebs/Ringer/phosphate buffer (pH
7.4) containing BSA (20mM) and glucose (5mM) for 30 min at 37°C in the presence or absence
of isoproterenol (2uM). The reaction was stopped on ice and media was carefully collected for
measurement of glycerol release (Free glycerol determination kit; Sigma).
After the differentiation, 3T3L1 cels were incubated in glucose transporter buffer (1mM
NACL, 0.8 mMMgSO47H20,5.36 mMKCl, 0.845mM NaH2PO4, 1.5mM CaCl2H2O, 25mM
Hepes, 0,02μM Fenol Red, 1% BSA,5mM glucose) for 30 min at 37°C in the presence or
absence of isoproterenol (10uM). The incubation medium was collectedfor measure of glycerol
release (Triacylglycerol Determination Kit, Labtest).
Results expressed as nmol of glycerol per 1x104primary adipocytes and mmol per gram for
3T3-L1.
Statistical Analysis
Statistical analysis was performed using the GraphPad Prism statistics software package ver-
sion 5.0 for Windows (GraphPad Software, San Diego, CA, USA). The data are expressed as
the means ± SD. Data were analyzed using a Student’s t-test for comparison between two
groups. Implementation of the Kolmogorov-Smirnov test revealed that the results of experi-
ments were distributed normally. For comparison of assays in cell culture, the ANOVA one-
way test or ANOVA two-way test with Bonferroni post-test were used. A value of P< 0.05,
P<0.01, P<0.001 was considered statistically significant.
Discussion
Previous results reported by our group demonstrated that in Wistar rats, the i.p administration
of doxorubicin promoted both a considerable weight loss and reduction in epididimal adipose
tissue. These results were similar to those found in the literature, where in low (2.5mg/Kg
weekly) doses of doxorubicin were reported to cause reductions in body and adipose tissue
weights [21–22]. Based on these findings, we proposed to investigate the toxicity of doxorubi-
cin, as well as its potential role in metabolic impairment in adipose tissue, as clinical studies
have demonstrated that a decrease in adipose mass is associated with a poor prognosis in can-
cer patients [23–25]. Here we showed that doxorubicin was toxic in a both models, causing
3T3-L1 cell death, and that doxorubicin administration could impair glucose uptake, lipogene-
sis, adipogenesis, and lipolysis both in vivo (15 mg/kg b.w. in rats) and in vitro (1 and 0.1 μMin
3T3-L1 cell culture). From our results, it is clear that doxorubicin treatment disrupt the adipose
tissue homeostasis.
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Doxorubicin reduced the viability of adipocytes in vitro (Fig 1A) and reduced the diameter of
adipocytes ex vivo (Fig 1B). WAT has an endocrine function; specifically, it produces and releases
adipokines that are important to the maintenance of physiological conditions [26] and supplies
the fatty acids needed for energy utilization during periods of energy deprivation [27–28].
WAT is an important tissue in the regulation of glucose homeostasis. In recent studies [29],
experiments involving subcutaneous adipose tissue transplantation in sedentary mice demon-
strated that the transplanted WAT sufficiently attenuated insulin resistance and thus improved
glucose tolerance.
In WAT, glucose uptake is stimulated by insulin. The i.p. administration of doxorubicin led
to a reduction in glucose uptake (Fig 2). Under physiological conditions, glucose is mainly
transported across the cell membrane through stimulation induced by GLUT-4 isoform trans-
location [30]. We observed that doxorubicin caused a reduction in GLUT-4 protein expression
and AMPK Thr172 phosphorylation in vivo (Fig 2D). The reduction of glucose uptake
observed in a 3T3-L1 cell-based in vitro assay was similar to that observed in ex vivoWAT (Fig
2A), except that AMPK Thr172 phosphorylation and GLUT-4 expression were not decreased
(Fig 2D and 2E).
The reduction in glucose uptake in insulin-stimulated cells might be attributable to the sig-
nificant (P< 0.01) decrease in Pparg expression (Fig 7A). The nuclear receptor PPARg is
strongly expressed in WAT. Activation of this receptor in response to the administration of
drugs from the thiazolidinedione family of agents is utilized clinically to increase insulin sensi-
tivity [31–32]. PPARg activation was shown to improve glucose uptake in adipocytes isolated
fromWAT by increasing GLUT-4 protein expression [33]. By the same token, inhibition of
PPARg reduced glucose uptake in adipocytes through reductions in GLUT-1 and GLUT-4
expression [34].
PPARg is the master transcription factor in adipose tissue. Beyond its function in glucose
homeostasis, this nuclear receptor is responsible for pleiotropic effects such as the modulation
of lipogenesis, adipogenesis, and lipolysis [35]. However, the mechanisms by which PPARg reg-
ulates these different metabolic processes depend on synergic actions with other transcription
factors [36–37].
Adiponectin, the most potent endogenous insulin sensitizing agent, is a protective hormone
produced by adipocytes and is important for maintaining energy homeostasis. Generally, the
plasma concentrations of adiponectin are inversely proportional to the level of insulin resistance
[38]. This effect is normally derived from the activation of AMPK and signaling molecules such
as the protein kinase RAS-associated protein Rab5, p38 mitogen-activated protein kinase, phos-
phoinositide-3-kinase, and AKT [39]. However, lower serum adiponectin levels were observed in
retroperitoneal adipose tissues and cell culture supernatants after doxorubicin treatment (Fig
3A–3C). It is important to note that Maruyana et al. (2011) found that the administration of adi-
ponectin protected animals against doxorubicin-induced cardiotoxicity via AKT signaling.
Taken together, decreases in PPARg and adiponectin could be the cause or effect of this pro-
nounced decrease in glucose uptake and homeostasis associated with doxorubicin treatment.
In addition to its effects on glucose uptake, doxorubicin disrupted several other metabolic
pathways, leading to a reduction in lipogenesis in vivo (Fig 4) that was accompanied by a
decrease in the gene expression of two master enzymes involved in de novo lipogenesis, Fas
and Acc (Fig 5). The reduced utilization of glucose to form triacylglycerol and the reduction in
Fas and Acc expression contributed to severe adipocyte biological side effects. Moreover,
GLUT-4 protein expression was dramatically reduced in the adipose tissues of rats treated with
doxorubicin. Similarly, lipogenesis is mainly regulated by insulin in adipose tissue [40].
Doxorubicin treatment impaired adipogenesis (Fig 6), as well as lipogenesis. Notably, doxo-
rubicin reduced the expression of C/ebpa, Pparg, and Srebp1c, which encode key regulators of
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adipocyte development. C/EBP belongs to a family of transcription factors that regulate other
transcription factors, which in turn induce Pparg expression. C/EBP also plays a critical role in
adipocyte development and, consequently, lipid accumulation or lipogenesis. SREBP1 is
another pro-adipogenic factor that appears to contribute to the expression of Pparg and C/ebpb
[41]. In an earlier report, doxorubicin suppressed adipogenesis after a brief exposure (3 h),
thus corroborating our findings. This inhibition was dose dependent, and expression of the
transcription factors C/EBPb and PPARg was also suppressed [42].
Ex vivo, both basal and stimulated lipolysis activities were reduced, and we also observed a
reduction in phosphorylation of the major lipase HSL at 565Ser and 660 Ser, as well as ATGL
in the retroperitoneal adipose tissues of rats treated with doxorubicin (Fig 8D). This reduction
in lipolysis was observed via a reduction in glycerol release from adipocytes. Lipolysis depends
on a cycle between fatty acid re-esterification and hydrolysis [28]. This is a plausible mecha-
nism for the doxorubicin-mediated disruption of lipolysis, but more studies are necessary.
In contrast, these conditions are antagonistic with regard to lipolysis. In cachexia, the reduc-
tion in adipose tissue is a consequence of elevated lipolysis (and HSL activity) [10], and a defi-
ciency in ATGL or HSL in tumor-bearing mice was shown to prevent lipolysis, as well as adipose
tissue and skeletal muscle wasting, thus increasing the survival rates in those modified mice [43].
These results indicate that a higher rate of lipolysis is necessary for cachexia development [43].
Taken together, our results demonstrate that doxorubicin treatment strongly affects adipose
tissue homeostasis. Both the endocrine and metabolic functions of adipose tissues were
impaired in response to doxorubicin. This dysfunction might have been caused by an increase
in adipocyte death. Adipose tissues from humans undergoing chemotherapy treatment exhib-
ited a similar phenomenon described as “fat necrosis” [44]. Fat necrosis is the result of adipose
tissue death in response to disease, injury, or pathologic conditions.
In conclusion, many side effects of doxorubicin chemotherapy treatment might be induced
by the effects of this agent on WAT. Side effects, such as endocrine and metabolic changes,
lead to a deep reduction in the quality of life of patients undergoing treatment. Therefore, our
results represent an important contribution to an understanding of the side effects observed in
patients undergoing chemotherapy and can facilitate the search for alternative treatments that
promote a better quality of life.
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